Publications
58
Citations
353
Est. group size
~26
Recurring co-author estimate
Active years
25
Publishing since 2002
Gabriela Sanchez-Petitto's work focuses on hematopoietic stem cell transplantation (a procedure that replaces a patient's blood-forming cells, often used to treat blood cancers) and its use in treating blood cancers like acute myeloid leukemia. Her research examines transplant outcomes, complications such as graft-versus-host disease and infections, and how pre-existing conditions like cardiovascular disease affect patient results. This work is clinically oriented, drawing on single-center experiences and multi-center clinical trials to improve transplant protocols and post-transplant care.
Publication output has grown over the last decade, rising from a few papers per year in 2017-2019 to a peak of 13 in 2025, indicating increasing research activity.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Cardiovascular Considerations After Cancer Therapy
JACC CardioOncology · 2025
- Oral Azacitidine Use after Stem Cell Transplantation for Myeloid Malignancies: A Single Center Experience
Transplantation and Cellular Therapy · 2025
- Letermovir Prophylaxis in Cytomegalovirus Seronegative Recipients with a Seropositive Donor Allogeneic Hematopoietic Cell Transplant: A Single-Center Experience
Transplantation and Cellular Therapy · 2025
- Outcomes of older matched sibling donors compared to younger matched unrelated donors in allogeneic hematopoietic cell transplantation for AML in first complete remission.
Journal of Clinical Oncology · 2025
- Unmasking Parvovirus B19 Infection After Allogeneic HSCT: Early Recognition and Effective Management
Transplant Infectious Disease · 2025
- Successful engraftment in myeloablative transplant with cadaveric bone marrow after sudden unavailability of living donor
Blood Advances · 2025
- Tocilizumab for cytokine release syndrome after allogeneic hematopoietic stem cell transplantation with post-transplant cyclophosphamide
Blood · 2025
- MO-TRANS update: A randomized, double-blind, placebo-controlled, multi-center phase III study of mocravimod (MOC) as maintenance treatment in AML patients undergoing allogeneic hematopoietic cell transplantation
Blood · 2025
- Real world experience of alpha-1 antitrypsin in steroid-refractory acute graft versus host disease: Higher durable response rate compared to ruxolitinib
Blood · 2025
- First report of successful, lifesaving and timely graft rescue using an off-the-shelf cryopreserved, cadaveric marrow in myeloablative transplant with an unexpected unavailability of a living matched unrelated donor.
Blood · 2025
- Clinical outcomes of patients with acute myeloid leukemia and cardiovascular disease
Leukemia Research · 2024
- Outcomes of Patients with Myeloid Malignancies and Cardiovascular Disease Undergoing Allogeneic Stem Cell Transplantation
Acta Haematologica · 2024
- MO-TRANS: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Phase III Study of Mocravimod (MOC) As Adjunctive and Maintenance Treatment in AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation
Blood · 2024
- Contemporary Clinical and Molecular Epidemiology of Vancomycin-Resistant Enterococcal Bacteremia: A Prospective Multicenter Cohort Study (VENOUS I)
UNC Libraries · 2024
- Umbilical Cord Blood Transplantation: Connecting Its Origin to Its Future
Stem Cells Translational Medicine · 2023
- Blood×16
- Clinical Lymphoma Myeloma & Leukemia×5
- Transplantation and Cellular Therapy×4
- British Journal of Haematology×3
- Leukemia Research×3
- Marcos J.G. De Lima
Medicine · The Ohio State University
- Karilyn Larkin
Medicine · The Ohio State University
- Malith Karunasiri
Medicine · The Ohio State University
- Alexander Rudich
Medicine · The Ohio State University
- James Ropa
Medicine · Indiana University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 19, 2026.
Claim or correct this profile